Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Not yet recruiting 3Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Thoracic 5

Conditions

Breast Neoplasms 10184Neoplasms 7810Carcinoma, Non-Small-Cell Lung 5760Prostatic Neoplasms 5024Colorectal Neoplasms 4606Lung Neoplasms 3725Leukemia, Myeloid, Acute 3102Neoplasm Metastasis 3083Multiple Myeloma 3082Pancreatic Neoplasms 2845Melanoma 2653Ovarian Neoplasms 2573Lymphoma 2571Carcinoma, Hepatocellular 2480Stomach Neoplasms 2330Recurrence 2230Head and Neck Neoplasms 2103Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2058Leukemia 2013Brain Neoplasms 1905Glioblastoma 1797Colonic Neoplasms 1791Leukemia, Lymphocytic, Chronic, B-Cell 1771Rectal Neoplasms 1720Uterine Cervical Neoplasms 1693Squamous Cell Carcinoma of Head and Neck 1654Lymphoma, Follicular 1652Lymphoma, Large B-Cell, Diffuse 1597Carcinoma, Renal Cell 1577

Interventions

Paclitaxel 2Cisplatin 2Carboplatin 2sintilimab 1osimertinib 1cemiplimab 1Surgical Procedures, Operative 1Platinum Compounds 1Pemetrexed 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Resectable Non-small Cell Lung Cancer × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

NCT05247684 2026-03-05

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Akeso

Phase 2 Active not recruiting
90 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

NCT07038460 2025-06-26

NEO-LISI

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
134 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

NCT06946836 2025-04-27

Neoadjuvant

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Not yet recruiting
80 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

NCT06485557 2024-07-03

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

Tang-Du Hospital

Phase 3 Not yet recruiting
90 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡